Cardiovascular disease predicts diabetic peripheral polyneuropathy in subjects with type 2 diabetes: A 10-year prospective study

European Journal of Cardiovascular Nursing

Volumn 15, Issue 4, 2016, Pages 248-254

  Ybarra Muñoz, Juan ^a   Jurado Campos, Jeronimo ^b,c   Garcia Gil, Maria ^b   Zabaleta Del Olmo, Edurne ^b,d   Mir Coll, Teresa ^c   Zabalegui, Adelaida ^e   Vidal, Josep ^e   Romeo, June H ^f  

^a HOSPITAL QUIRÓN   (Spain)

^b Research Institute University Primary Care IDIAP Jordi Gol   (Spain)

^c INSTITUT CATALÀ DE LA SALUT   (Spain)

^d UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^e HOSPITAL CLÍNIC   (Spain)

^f LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Cardiac autonomic neuropathy; cardiovascular disease; diabetic peripheral neuropathy; low density lipoprotein cholesterol; prospective studies; type 2 diabetes mellitus

Indexed keywords

LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; CORONARY ARTERY DISEASE; DIABETIC NEUROPATHY; DISEASE COURSE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; NERVE CONDUCTION; NEUROLOGIC EXAMINATION; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL ISCHEMIA; PREDICTION; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCORING SYSTEM; CROSS-SECTIONAL STUDY; POLYNEUROPATHY; RISK FACTOR;

CARDIOVASCULAR DISEASES; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; HUMANS; POLYNEUROPATHIES; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 84971475226     PISSN: 14745151     EISSN: 18731953     Source Type: Journal    
DOI: 10.1177/1474515114565215     Document Type: Article

References (47)

1. Holzer SE, Camerota A, Martens L, et al. Costs and duration of care for lower extremity ulcers in patients with diabetes. Clin Ther 1998; 20: 169-181.
2. Mayfield JA, Reiber GE, Sanders LJ, et al. Preventive foot care in people with diabetes. Diabetes Care 1998; 21: 2161-2177.
3. Boulton AJ, Vinik AI, Arezzo JC, et al. Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care 2005; 28: 956-962.
4. Kärvestedt L, Mårtensson E, Grill V, et al. Peripheral sensory neuropathy associates with micro- or macroangiopathy: results from a population-based study of type 2 diabetic patients in Sweden. Diabetes Care 2009; 32: 317-322.
5. Gordois A, Scuffham P, Shearer A, et al. The health care costs of diabetic peripheral neuropathy in the U.S. Diabetes Care 2003; 26: 1790-1795.
6. American Diabetes Association. Economic costs of diabetes in the U.S. in 2007. Diabetes Care 2008; 31: 596-615.
7. Boulton AJ, Vileikyte L,. The diabetic foot: the scope of the problem. J Fam Pract 2000; 49 (11 Suppl.): S3-S8.
8. World Health Organization. Fact sheet 312, diabetes., http://www.who.int/mediacentre/factsheets/fs312/en/ (2012,. accessed 1 November 2014).
9. Haffner SM, Lehto S, Rönnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 23; 339 (4): 229-234.
10. Lawlor DA, Fraser A, Ebrahim S, et al. Independent associations of fasting insulin, glucose, and glycated haemoglobin with stroke and coronary heart disease in older women. PLoS Med 2007; 4: e263.
11. Mazzone T, Meyer PM, Kondos GT, et al. Relationship of traditional and nontraditional cardiovascular risk factors to coronary artery calcium in type 2 diabetes. Diabetes 2007; 56: 849-855.
12. Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Eng J Med 2003; 348: 383-393.
13. Pop-Busui R, Evans GW, Gerstein HC, et al. Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of cardiac autonomic dysfunction on mortality risk in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Diabetes Care 2010; 33: 1578-1584.
14. Hsu WC, Chiu SY, Yen AM, et al. Somatic neuropathy is an independent predictor of all- and diabetes-related mortality in type 2 diabetic patients: a population-based 5-year follow-up study (KCIS No. 29). Eur J Neurol 2012; 19: 1192-1198.
15. Elliott J, Tesfaye S, Chaturvedi N, et al. Large-fiber dysfunction in diabetic peripheral neuropathy is predicted by cardiovascular risk factors. Diabetes Care 2009; 32: 1896-1900.
16. Chung JO, Cho DH, Chung DJ, et al. Association between diabetic polyneuropathy and cardiovascular complications in type 2 diabetic patients. Diabetes Metab J 2011; 35: 390-396.
17. Brownrigg JR, de Lusignan S, McGovern A, et al. Peripheral neuropathy and the risk of cardiovascular events in type 2 diabetes mellitus. Heart 2014; 100 (23): 1837-43.
18. Jurado J, Ybarra J, Solanas P, et al. Prevalence of cardiovascular disease and risk factors in a type 2 diabetic population of the North Catalonia diabetes study. J Am Acad Nurse Pract 2009; 21: 140-148.
19. Diagnosis and classification of diabetes mellitus (WHO/NCD/NCS/99.2). Geneva: World Health Organization, 1999.
20. Jurado J, Ybarra J, Romeo JH, et al. Clinical screening and diagnosis of diabetic polyneuropathy: the North Catalonia Diabetes Study. Eur J Clin Invest 2009; 39: 183-189.
21. Jurado J, Ybarra J, Romeo JH, et al. Angiotensin-converting enzyme gene single polymorphism as a genetic biomarker of diabetic peripheral neuropathy: longitudinal prospective study. J Diabetes Complications 2012; 26: 77-82.
22. Tesfaye S, Chaturvedi N, Eaton SE, et al. for the EURODIAB Prospective Complications Study Group. Vascular risk factors and diabetic neuropathy. N Engl J Med 2005; 352: 341-350.
23. Sibal L, Law HN, Gebbie J, et al. Cardiovascular risk factors predicting the distal symmetrical polyneuropathy in people with type 1 diabetes: A 9-year follow-up study. Ann N Y Acad Sci 2006; 1084: 304-318.
24. Sima AA, Kamiya H,. Diabetic neuropathy differs in type 1 and type 2 diabetes. Ann N Y Acad Sci 2006; 1084: 1235-1249.
25. Owolabi MO, Ipadeola A, Adeleye JO,. Aggregate cardiovascular risk is a stronger statistical correlate of clinically evident diabetic peripheral neuropathy than HbA1c alone. J Natl Med Assoc 2010; 102: 707-712.
26. Owolabi MO, Ipadeola A,. Total vascular risk as a strong correlate of severity of diabetic peripheral neuropathy in Nigerian Africans. Ethn Dis 2012; 22: 106-112.
27. Maser RE, Mitchell BD, Vinik AI, et al. The association between cardiovascular autonomic neuropathy and mortality in individuals with diabetes: a meta-analysis. Diabetes Care 2003; 26: 1895-1901.
28. Vinik AI, Erbas T,. Diabetic autonomic neuropathy. Handb Clin Neurol 2013; 117: 279-294.
29. Vinik AI, Erbas T, Stansberry KB, et al. Small fiber neuropathy and neurovascular disturbances in diabetes mellitus. Exp Clin Endocrinol Diabetes 2001; 109 (Suppl. 2): S451-S473.
30. Vinik AI, Maser RE, Ziegler D,. Neuropathy: the crystal ball for cardiovascular disease? Diabetes Care 2010; 33: 1688-1690.
31. Baldereschi MI, Inzitari M, Di Carlo A, et al. Vascular factors predict polyneuropathy in a non-diabetic elderly population. Neurol Sci 2013; 34: 955-962.
32. Herder C, Lankisch M, Ziegler D, et al. Subclinical inflammation and diabetic polyneuropathy: MONICA/KORA Survey F3 (Augsburg, Germany). Diabetes Care 2009; 32: 680-682.
33. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
34. Callaghan BC, Cheng HT, Stables CL, et al. Diabetic neuropathy: clinical manifestations and current treatments. Lancet Neurol 2012; 11: 521-534.
35. Jang EH, Park YM, Hur J, et al. Higher levels of small dense low-density lipoprotein (LDL) are associated with cardiac autonomic neuropathy in patients with type 2 diabetes. Diabet Med 2013; 30: 694-701.
36. Wiggin TD, Sullivan KA, Pop-Busui R, et al. Elevated triglycerides correlate with progression of diabetic neuropathy. Diabetes 2009; 58: 1634-1640.
37. Padilla A, Descorbeth M, Almeyda AL, et al. Hyperglycemia magnifies Schwann cell dysfunction and cell death triggered by PA-induced lipotoxicity. Brain Res 2011; 1370: 64-79.
38. McCall KD, Holliday D, Dickerson E, et al. Phenylmethimazole blocks palmitate-mediated induction of inflammatory cytokine pathways in 3T3L1 adipocytes and RAW 264.7 macrophages. J Endocrinol 2010; 207: 343-353.
39. Vincent AM, Hayes JM, McLean LL, et al. Dyslipidemia-induced neuropathy in mice: the role of oxLDL/LOX-1. Diabetes 2009; 58: 2376-2385.
40. Vincent AM, Callaghan BC, Smith AL, et al. Diabetic neuropathy: cellular mechanisms as therapeutic targets. Nat Rev Neurol 2011; 7: 573-583.
41. Jang ER, Lee CS,. 7-ketocholesterol induces apoptosis in differentiated PC12 cells via reactive oxygen species-dependent activation of NF-kappa B and Akt pathways. Neurochem Int 2011; 58: 52-59.
42. Toth PP, Simko RJ, Palli SR, et al. The impact of serum lipids on risk for microangiopathy in patients with type 2 diabetes mellitus. Cardiovasc Diabetol 2012; 14: 109.
43. Boussageon R, Supper I, Erpeldinger S, et al. Are concomitant treatments confounding factors in randomized controlled trials on intensive blood-glucose control in type 2 diabetes? a systematic review. BMC Med Res Methodol 2013; 30: 107.
44. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317: 703-713.
45. Keech AC, Mitchell P, Summanen PA, et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet 2007; 370: 1687-1697.
46. American Diabetes Association. American Academy of Neurology Report and recommendations of the San Antonio Conference on Diabetic Neuropathy (Consensus Statement). Diabetes Care 1988; 11: 592-597.
47. Tesfaye S, Boulton AJ, Dyck PJ, et al. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care 2010; 33: 2285-2293.